
    
      This study is a prospective, controlled, randomized single blind clinical trial of subjects
      with benign prostatic hyperplasia, which will allow for an interim analysis for sample size
      adjustment. Subjects first will be randomized in a 2:1 proportion in favor of the Treatment
      arm. Subjects in the Control arm will be allowed to crossover to have the RezÅ«m treatment
      after the 3-month follow-up examination.
    
  